Shuttle Pharma shareholders approve reverse stock split authorization up to 1:150 at annual meeting

Shuttle Pharmaceuticals Holdings, Inc.

All four director nominees elected with ~2.6M votes each; broker non-votes 582,364.
Ratification of Forvis Mazars as auditor approved 3,191,174 for, 12,417 against.
Say-on-pay advisory vote approved 2,650,932 for, 39,906 against.
Authorization for board to effect reverse stock split (1:2 to 1:150) approved 3,055,436 for, 119,431 against.
Meeting adjournment proposal also approved 3,077,059 for, though not needed.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal No. 1: Election of Directors Nominee Name For Withheld Broker Non-Votes Christopher Cooper 2,621,457 171,251 582,364 Adam Chambers 2,616,680 176,028 582,364 George Scorsis 2,664,628 128,080 582,364 Angel Liriano 2,664,666 128,042 582,364 A plurality of the votes cast at the Meeting was required to approve the election of each of the nominees listed above as directors to serve until the 2027 annual meeting of the Company’s stockholders and until each of their respective successors are elected and qualified or until each of their earlier resignation or removal (“Proposal No. 1”). Accordingly, Proposal No. 1 was approved

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Ratification of Appointment of Forvis Mazars, LLP as the Company’s Independent Registered Public Accounting Firm at the 2026-05-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal No. 2: Ratification of Appointment of Forvis Mazars, LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026. For Against Abstentions 3,191,174 12,417 171,481

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-21 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal No. 3: Advisory Vote on Executive Compensation (“Say on Pay”) For Against Abstentions Broker Non-Votes 2,650,932 39,906 101,870 582,364

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Authorization of the Board of Directors to Effect one or more Reverse Stock Split(s) of the Common Stock at a Ratio Between 1-for-2 and 1-for-150 at the 2026-05-21 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal No. 4: Authorization of the Board of Directors to Effect one or more Reverse Stock Split(s) of the Common Stock at a Ratio Between 1-for-2 and 1-for-150 For Against Abstentions 3,055,436 119,431 200,205

View on SEC.gov

216 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-025340

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.